Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

Journal for Immunotherapy of Cancer
Michael LattanziAnna C Pavlick

Abstract

Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls. All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to historical control patients identified via a prospective institutional database with protocol-driven follow-up. Survival times were calculated using the Kaplan-Meier method, and Cox proportional hazard models were employed to identify significant prognostic factors and control for confounding variables. A total of 91 patients were treated with an NY-ESO-1 vaccine for the treatment of high-risk resected melanoma. Of this group, 67 patients were stage III and were selected for comparative analysis with 123 historical control patients with resected stage III melanoma who received no adjuvant therapy. Among the pooled vaccine cohort (median fo...Continue Reading

References

Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y T ChenL J Old
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·E JägerA Knuth
Mar 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·G ZengR F Wang
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·A A JungbluthL J Old
Aug 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Sacha GnjaticLloyd J Old
Mar 6, 2004·Seminars in Cancer Biology·Vernon K Sondak, Jeffrey A Sosman
Apr 6, 2004·The Prostate·Alexander FossåErlend B Smeland
Jul 15, 2004·Proceedings of the National Academy of Sciences of the United States of America·Ian D DavisJonathan S Cebon
Jul 22, 2005·Nature Reviews. Cancer·Andrew J G SimpsonLloyd J Old
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Catherine BarrowJonathan Cebon
Sep 21, 2006·Proceedings of the National Academy of Sciences of the United States of America·Elke JägerAlexander Knuth
Jul 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·Kunle OdunsiSacha Gnjatic
Jan 2, 2008·American Journal of Obstetrics and Gynecology·Chiara NapoletanoPierluigi Benedetti Panici
Jun 21, 2008·The New England Journal of Medicine·Naomi N HunderCassian Yee
Jun 21, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sylvia AdamsNina Bhardwaj
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul F RobbinsSteven A Rosenberg
Jun 3, 2011·The New England Journal of Medicine·Douglas J SchwartzentruberPatrick Hwu
Mar 29, 2012·Proceedings of the National Academy of Sciences of the United States of America·Kunle OdunsiElke Jäger
Oct 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paola FilipazziLicia Rivoltini
Nov 28, 2014·Orphanet Journal of Rare Diseases·Stuart A Bell, Catrin Tudur Smith
Dec 3, 2014·Pediatric Neurology·Ahmad Ghanizadeh, Anaheed Ayoobzadehshirazi
Jan 31, 2015·Cancer Immunology Research·Rachel Lubong SabadoNina Bhardwaj
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert H I AndtbackaRobert S Coffin
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Dec 17, 2015·JAMA : the Journal of the American Medical Association·Stephan EhrhardtCurtis L Meinert
Mar 20, 2016·British Journal of Anaesthesia·S HeschlM Rigaud
May 6, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick A Ott, F Stephen Hodi
Sep 12, 2017·The New England Journal of Medicine·Georgina V LongJohn M Kirkwood
Sep 12, 2017·The New England Journal of Medicine·Jeffrey WeberUNKNOWN CheckMate 238 Collaborators

❮ Previous
Next ❯

Citations

Dec 24, 2018·Journal of Surgical Oncology·Joseph G CromptonMary S Brady
Jun 23, 2020·Biomicrofluidics·Molly Kozminsky, Lydia L Sohn
Nov 18, 2018·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Jonathan Cebon
May 4, 2021·The Journal of Clinical Investigation·Tomohiro EnokidaNina Bhardwaj

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
surgical resections

Clinical Trials Mentioned

NCT00124124
NCT00821652
NCT01079741

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.